New Thermage FLX™ System Reduces Treatment Time by 25 Percent and Enhances Patient Comfort
LAVAL, Quebec, Oct. 4, 2017 /PRNewswire/ -- Solta Medical,
a division of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant"), announced today that its Thermage
FLX™ System received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to non-invasively smooth skin on the face,
eyes and body.
Thermage FLX is the newest generation of Thermage® technologies known for non-invasively reducing the appearance of fine lines
and wrinkles. The system uses patented radiofrequency technology to create a uniform heating effect in the deep collagen-rich
layers of the skin. This gentle heating tightens existing collagen and stimulates the production of new collagen, all with
little-to-no downtime for the patient. The Thermage FLX features a new optimized energy delivery algorithm, known as AccuREP™
technology, which automatically measures and precisely tunes the amount of energy delivered to the patient and treatment area.
The system also features a new vibrating hand-piece to help enhance patient comfort, and a new, larger treatment tip that reduces
treatment time by 25 percent.
"As the demand for skin tightening procedures continues to rise, we have continued to evolve and enhance our Thermage
technology to meet the needs of skincare physicians and their patients who are looking for ways to achieve smoother skin with
natural looking results," said Joseph C. Papa, chairman and CEO, Valeant. "With the approval of
the Thermage FLX through our Solta business, a pioneer and leader in the aesthetic industry, treatments are now faster and more
patient-friendly."
The non-invasive treatment of addressing the look and feel of aging skin using radiofrequency energy was first introduced by
Thermage more than 15 years ago. Since that time, the technology has continued to evolve, and to date, two million Thermage
treatments for women and men of all ethnicities have been performed.
"Being among the first adopters of the technology, I have confidently used the system for over a decade, as it is the
center-piece of a successful skin tightening program," said Michael S. Kaminer, M.D., founding
partner of SkinCare Physicians. "The Thermage system, backed by more than 50 clinical studies, is the gold standard in our
practice and our most popular skin smoothing treatment. I'm excited to see what the new Thermage FLX system has to offer as each
subsequent version has proven to exceed my expectations."
The new Thermage FLX system is expected to be commercially available before the end of 2017.
About Solta Medical
Solta Medical, a Valeant Pharmaceuticals International, Inc. company , is a global leader in the medical
aesthetics market that helps drive revenue growth to aesthetic practices by providing innovative and effective skin rejuvenation
and body contouring solutions. Solta offers seven aesthetic energy devices to address a range of skin-related concerns, including
skin resurfacing and rejuvenation, body contouring, fat reduction, skin smoothing, hair removal, and acne reduction. More than
five million procedures have been performed with Solta Medical's portfolio of products around the world. More information can be
found at www.solta.com.
About Valeant
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that
develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology,
gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found
at www.valeant.com.
Forward-looking Statements
This press release may contain forward-looking statements which may generally be identified by the use of the words
"anticipates, "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential,"
"target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and
beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and
uncertainties discussed in the Company's most recent annual or quarterly report and detailed from time to time in Valeant's other
filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated
herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These
forward-looking statements speak only as of the date hereof. Valeant undertakes no obligation to update any of these
forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes,
unless required by law.
View original content with multimedia:http://www.prnewswire.com/news-releases/solta-medical-receives-fda-510k-clearance-for-thermage-flx-system-newest-generation-skin-smoothing-technology-300530165.html
SOURCE Valeant Pharmaceuticals International, Inc.